TGase Protein Labeling Kits

Transglutaminase Labeling Kits are designed to easily obtain mg amounts of labeled proteins.

Transglutaminase enzymatic labeling requires accessible glutamine or lysine residues on your target protein's surface. Therfore in a first step Substrate Finder Kit (L001) characterizes your target protein: it contains accesible glutamine residues or lysine residues or both or it isn’t a substrate at all.
Substrate Finder Kit (L001) will indicate which Labeling Kit is appropriate to modify your target protein with the desired labels: Biotin, PEG1,088, PEG5,000 or ATTO-488TM, ATTO-532TM , ATTO-550TM, ATTO-647NTM, ATTO-700TM,

Please contact us if you are interested in other labels.



Art. No.
Name
Quantity
Price
L001 Substrate Finder Kit
1 Kit
390 €

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy